**3. Intra-pediatric gastrointestinal endoscopic management period**

Any time sedative and analgesic medications are to be given to a pediatric patient, a clearly worded informed consent should be obtained. This consent should include a listing of the possible consequences of adverse drug reactions, allergic reactions and airway difficulties. Prior to undertaking intravenous sedation, there are some key pieces of equipment that must be in place. These equipments that should be in place before starting a sedation are suction, oxygen, airway, pharmacy, monitors, and extra equipment such as defibrillator (SOAPME) (Cote et al., 2006). In general, intravenous sedation for pediatric gastrointestinal endoscopic procedures is done by anesthesiologists or anesthetic personnel directly supervised by the anesthesiologist or anesthetic personnel.

 In a developing country where pediatric endoscopy is performed at increasing rates, the majority of cases (as noted by anecdotal observation) are treated under general anesthesia in the operating room. At Siriraj Hospital, there is a dedicated endoscopy unit with dedicated anesthesia service. Over the last four years, 2006–2010, we performed most pediatric gastrointestinal endoscopic procedures with intravenous sedation technique. We followed the guidelines provided by the American Academy of Pediatrics (Cote et al., 2006) and American Society of Anesthesiologists standards (ASA, 2002). Our review of intravenous sedation practice in pediatric population showed that intravenous sedation can be done safely with various sedative combinations with proper monitoring and anesthesiology service supervision.

Patient monitoring during the procedure should be included continuous monitoring of heart rate and oxygen saturation, and intermittent recording of respiratory rate and blood pressure. Additionally, capnography detects increasing levels of carbon dioxide before desaturation occurs and can detect early inadequately ventilation (Krauss & Green, 2000). However, the cost of capnometer is relatively high. The developing countries like Thailand have none or few capnometers, though this monitor is not routinely used. A sedative drug can only be considered safe after experience in hundreds or thousands of cases. Good protocols are important for the safety and success of the intravenous sedation technique. Depending on the procedure, pediatric intravenous sedation can involve monotherapy or combination therapy. Each regimen and administration of intravenous sedation must be carefully personalized for each patient. When administered, the drugs should be given as an appropriate initial dose with subsequent doses until titrated to effect. However, the most important factor is the judgement of the physician (ASA, 2002; Sury, 2004; Cote et al., 2006; Krauss & Green, 2006; Vespasiano et al., 2007; Meredith et al., 2008).

Common drug-receptor systems used by anesthesiologists in Thailand include the following:


Sedation should be administered based on the patient's weight and titrated by response. Dosing requirements for individual patients may vary significantly based on the patient's psychosocial development and attention to the surrounding environment by the endoscopy team. Adequate time should be allowed between doses to assess sedation effects and determine the need for additional medication. For example, midazolam should be titrated to the effect with at least three minutes between doses, while fentanyl should have five minutes between doses. Higher doses of sedative/analgesic agents are frequently needed in preschool, school aged and preteen patients compared with those used in teenage children. The most common intravenous sedation regimen for pediatric gastrointestinal endoscopic procedure is the use of an opioid and a benzodiazepine combination to achieve analgesia and amnesia (Dar & Shah, 2010). Many safe regimens were reported. Consequently, anesthesiologist or the anesthetic personnel must exercise extreme caution while administering the intravenous sedation for pediatric gastrointestinal endoscopic procedure. The use of intravenous sedation drugs is reliability, efficacy and easy titration to achieve the end point. However, monitoring during the procedure is essential.

#### **3.1 Analgesic drugs**

#### **3.1.1 Fentanyl**

54 Gastrointestinal Endoscopy

In this report, the author will seek to examine the role of anesthesiologists in determining the field of pediatric intravenous sedation, and the current status of intravenous sedation for pediatric gastrointestinal endoscopic procedures in Siriraj GI Endoscopy Center, Siriraj Hospital, Thailand. Additionally, this review is divided into three parts: 1. the pre-pediatric gastrointestinal endoscopic assessment period, 2. the intra-pediatric gastrointestinal endoscopic management period, and 3. the post-pediatric gastrointestinal endoscopy period.

The general health status of each patient undergoing pediatric procedural intravenous sedation must be evaluated. A physical examination should focus primarily on the upper airway, lungs, cardiovascular system, and baseline neurological status. To aid in assessment risk, the American Society of Anesthesiologists (ASA) has developed a classification system for patients, which categorizes individuals on a general health basis. Several studies have documented the fact that sedation risk in children rises with increasing ASA physical status (Cote et al., 2006; Krauss & Green, 2006; Vespasiano et al., 2007). ASA physical status 1 and 2 are considered low risk patient populations. ASA physical status 3 and 4 are high risk patient populations. The specific high risk patient populations in which anesthesia consultation may be warranted including known respiratory or hemodynamic instability, obstructive sleep apnea, high risk airway management, ASA physical status ≥4, infants born <37 weeks and <60 weeks post conception, history of sedation related adverse events, and

**2. Pre-pediatric gastrointestinal endoscopic assessment period** 

patients with neuromuscular disease affecting respiratory or brain stem function.

**3. Intra-pediatric gastrointestinal endoscopic management period** 

supervised by the anesthesiologist or anesthetic personnel.

room.

In this pre-assessment period, there are no differences in a routine practice between the developed countries and the developing countries. Additionally, the majority of intravenous sedation practices for pediatric gastrointestinal endoscopic procedures in the developing countries were sedated by anesthesiologists and/or anesthetic personnel in the operating

Any time sedative and analgesic medications are to be given to a pediatric patient, a clearly worded informed consent should be obtained. This consent should include a listing of the possible consequences of adverse drug reactions, allergic reactions and airway difficulties. Prior to undertaking intravenous sedation, there are some key pieces of equipment that must be in place. These equipments that should be in place before starting a sedation are suction, oxygen, airway, pharmacy, monitors, and extra equipment such as defibrillator (SOAPME) (Cote et al., 2006). In general, intravenous sedation for pediatric gastrointestinal endoscopic procedures is done by anesthesiologists or anesthetic personnel directly

 In a developing country where pediatric endoscopy is performed at increasing rates, the majority of cases (as noted by anecdotal observation) are treated under general anesthesia in the operating room. At Siriraj Hospital, there is a dedicated endoscopy unit with dedicated anesthesia service. Over the last four years, 2006–2010, we performed most pediatric gastrointestinal endoscopic procedures with intravenous sedation technique. We followed the guidelines provided by the American Academy of Pediatrics (Cote et al., 2006) and American Society of Anesthesiologists standards (ASA, 2002). Our review of intravenous sedation practice in pediatric population showed that intravenous sedation can be done

Fentanyl is a potent synthetic opioid with no intrinsic anxiolytic or amnestic properties. It has high lipid solubility allows for quick penetration of the blood-brain barrier, resulting in a very rapid onset of action (<1 minute) and short duration of action (30-45 minutes) (Nowicki & Vaughn, 2002; Dar & Shah, 2010). Fentanyl lacks of direct of myocardial depressant effects, and absence of histamine release, making it an excellent choice for intravenous sedation. Intravenous fentanyl can be easily and rapidly titrated for painful procedures (Kennedy et al., 1998; Pitetti et al., 2003). The combination of fentanyl and midazolam is a popular intravenous sedation regimen, with a safety profile when both

Intravenous Sedation for Pediatric Gastrointestinal Endoscopy in a Developing Country 57

gastroenterologist. The use of propofol in pediatric population has been shown to be safe, effective, and reliable (Balsells et al., 1997; Kaddu et al., 2002). The drug, now commonly used outside the operating room, has demonstrated an excellent safety profile, despite a narrow therapeutic window. Desirable properties of propofol for endoscopic procedures include ease of use, quick onset of action, and rapid metabolization leading to shorter

Midazolam is the drug most commonly used for sedation in children during procedures (Kennedy et al., 1998; Pena & Krauss, 1999). It is a shorting, water soluble benzodiazepine with anxiolytic, amnestic, sedative, muscle relaxant, and anticonvulsant properties. It is very widely used because of its more rapid onset of action and shorter duration of effect compared with diazepam (Tolia et al., 2000). Disadvantages of midazolam include transient hypotension and vomiting. Midazolam is approved for many routes, including intravenous, oral and nasal and is most useful for intravenous sedation. Because of greater clearance of midazolam in children, larger weight-adjusted dosages may be required in pediatric patients than in adult to achieve similar levels and duration of sedation (Gilger, 1993 & Tolia et al., 2000). The shorter clinical half-life of the drug necessitates additional boluses for longer or complicated procedures. Less midazolam is needed when fentanyl is administered than when meperidine is given with midazolam. Initial intravenous dose of midazolam is 0.025-0.1 mg/kg and may repeat another dose, but the maximum recommended dose is 0.4- 0.6 mg/kg. In our endoscopy center, we commonly use midazolam combined with low dose

Ketamine is a phencyclidine derivative with dissociative sedative, analgesic and amnestic properties (Green & Krauss, 2000). It is one of the most sedative-analgesic agents and results in a number of desired clinical effects that are dose dependent (Krystal et al., 1994). Typically spontaneous respiration and airway reflexes are maintained although may not be totally normal. Neuropsychiatric effects of ketamine include visual hallucinations that may be accompanied by emergence phenomena and agitation. Ketamine generally causes an increase in heart rate, blood pressure, cardiac output, intracranial pressure, and intraocular pressure. Ketamine can induce salivation, and cholinergics have traditionally been coadministered. The single most severe adverse effect with ketamine sedation is laryngospasm. Ketamine is clinically effective by a number of different routes. Intravenous dose of ketamine is 1-1.5 mg/kg, and may repeat dose every 10 minutes as needed. In Thailand, we commonly used low dose of ketamine, and combined with low dose of midazolam, opioid drug, and/or low dose of propofol (Amornyotin et al., 2009). This combination technique produces stable

The ideal combination of sedative drugs for intravenous sedation in pediatric patients undergoing gastrointestinal endoscopic procedure is unknown. The drug combination provides synergistic action while lowering the doses of each agent. The combination regimen may be a superior sedation technique (Cohen et al., 2004; Van Natta & Rex, 2006). Our practice reflects this technique where many different combination regimens were used. Midazolam and fentanyl are the most common agents used in combination with propofol in this study. The next most common combination includes midazolam, fentanyl, ketamine,

hemodynamic effects, and can reduce the sedation related adverse effects.

recovery time (Aouad M.T. et al., 2008).

propofol and/or low dose fentanyl.

**3.2.2 Midazolam** 

**3.2.3 Ketamine** 

and propofol.

drugs are carefully titrated (Kennedy et al., 1998; Pena & Krauss, 1999; Pitetti et al., 2003). Fentanyl can cause respiratory depression and apnea, especially when combined with other sedatives or in infants less than 3 months of age (C.L. Algren & C.T. Algren, 1997). Fentanylinduced bradycardia may need treatment with a vagolytic drug such as atropine. Chest wall and glottic rigidity has been observed with rapid administration of fentanyl. Safe intravenous administration therefore requires slow titration of 0.5-1.0 mcg/kg boluses, and may repeat every 3 minutes, but the maximum cumulative dose is 4 to 5 mcg/kg in one hour (Tolia et al., 2000).

#### **3.1.2 Meperidine (Pethidine)**

Meperidine is a synthetic opioid and has grown out of favor in past years. The metabolites of meperidine are toxic to the central nervous system at high doses and in patients with renal impairment. Meperidine has a long and favorable experience in intravenous sedation for pediatric gastrointestinal endoscopic procedure (Bahal-O'Mara et al., 1993). Meperidine 0.5-1.0 mg/kg i.v. combined with midazolam 0.05-0.1 mg/kg i.v. provides effective sedation for gastrointestinal endoscopy. However, meperidine is not recommended for intravenous sedation in the emergency department (Lewis & Stanley, 1999; Mace, 2004). Side effects of meperidine are respiratory depression, nausea, vomiting, and dysphoria (Goad & Webster, 1997). It causes less histamine release and urticaria than morphine (C.L. Algren & C.T. Algren, 1997). Fatal reactions have also occurred in patients taking monoamine oxidase inhibitors.

#### **3.2 Sedative drugs**

#### **3.2.1 Propofol**

Propofol is a phenol derivative with sedative, hypnotic and anesthetic properties. It has a rapid onset (< 1 minute), shorter duration of action, and rapid recovery. Its clinical effects are dose dependent. Propofol has antiemetic, anxiolytic, hypnotic, amnestic and anesthetic properties. However, it does not have analgesic effects. Propofol can be given to children in the settings of gastroenterology (Barbi et al., 2003; Amornyotin et al., 2009, 2010), emergency department (Bassett et al., 2003; Green & Krauss, 2003), and critical care series (Lowrie et al., 1998) with good efficacy, rapid recovery, and apparent safety. The most serious adverse effect of propofol is potent respiratory depression and apnea can occur suddenly. The respiratory depression rates vary extensively by the study (Green & Krauss, 2003). Propofol can also produce hypotension, although this effect is typically transient and of little clinical importance in healthy patients (Green & Krauss, 2003). Propofol is well known to be painful upon injection, the addition of lidocaine has been shown to decrease the incidence of pain during injection (Bassett et al., 2003).

Currently, most centers utilize an anesthesiologist or nurse anesthetist to administer propofol (Sury & Smith, 2008), although recently nurse administered and patient controlled dosing has been reported in adult patients. In our endoscopy center, propofol is also administered by an anesthesiologist or nurse anesthetist. Propofol provides equal or better control and more rapid recovery when compared with midazolam for sedation (O'Hare et al., 2001). Initial intravenous bolus dose of propofol is 1.0 mg/kg and is followed by 0.5 mg/kg, and the repeated dose is needed. In my experience, I use the initial bolus dose of propofol and follow by the continuous intravenous technique. The continuous intravenous infusion of propofol dose is 100-150 mcg/kg/min. Majority of our patients received propofol in combination with other sedatives. Over the last decade, the use of propofol for endoscopic sedation has increased. It has gained wide acceptance among adult gastroenterologist. The use of propofol in pediatric population has been shown to be safe, effective, and reliable (Balsells et al., 1997; Kaddu et al., 2002). The drug, now commonly used outside the operating room, has demonstrated an excellent safety profile, despite a narrow therapeutic window. Desirable properties of propofol for endoscopic procedures include ease of use, quick onset of action, and rapid metabolization leading to shorter recovery time (Aouad M.T. et al., 2008).

#### **3.2.2 Midazolam**

56 Gastrointestinal Endoscopy

drugs are carefully titrated (Kennedy et al., 1998; Pena & Krauss, 1999; Pitetti et al., 2003). Fentanyl can cause respiratory depression and apnea, especially when combined with other sedatives or in infants less than 3 months of age (C.L. Algren & C.T. Algren, 1997). Fentanylinduced bradycardia may need treatment with a vagolytic drug such as atropine. Chest wall and glottic rigidity has been observed with rapid administration of fentanyl. Safe intravenous administration therefore requires slow titration of 0.5-1.0 mcg/kg boluses, and may repeat every 3 minutes, but the maximum cumulative dose is 4 to 5 mcg/kg in one

Meperidine is a synthetic opioid and has grown out of favor in past years. The metabolites of meperidine are toxic to the central nervous system at high doses and in patients with renal impairment. Meperidine has a long and favorable experience in intravenous sedation for pediatric gastrointestinal endoscopic procedure (Bahal-O'Mara et al., 1993). Meperidine 0.5-1.0 mg/kg i.v. combined with midazolam 0.05-0.1 mg/kg i.v. provides effective sedation for gastrointestinal endoscopy. However, meperidine is not recommended for intravenous sedation in the emergency department (Lewis & Stanley, 1999; Mace, 2004). Side effects of meperidine are respiratory depression, nausea, vomiting, and dysphoria (Goad & Webster, 1997). It causes less histamine release and urticaria than morphine (C.L. Algren & C.T. Algren, 1997). Fatal reactions have also occurred in patients taking monoamine oxidase inhibitors.

Propofol is a phenol derivative with sedative, hypnotic and anesthetic properties. It has a rapid onset (< 1 minute), shorter duration of action, and rapid recovery. Its clinical effects are dose dependent. Propofol has antiemetic, anxiolytic, hypnotic, amnestic and anesthetic properties. However, it does not have analgesic effects. Propofol can be given to children in the settings of gastroenterology (Barbi et al., 2003; Amornyotin et al., 2009, 2010), emergency department (Bassett et al., 2003; Green & Krauss, 2003), and critical care series (Lowrie et al., 1998) with good efficacy, rapid recovery, and apparent safety. The most serious adverse effect of propofol is potent respiratory depression and apnea can occur suddenly. The respiratory depression rates vary extensively by the study (Green & Krauss, 2003). Propofol can also produce hypotension, although this effect is typically transient and of little clinical importance in healthy patients (Green & Krauss, 2003). Propofol is well known to be painful upon injection, the addition of lidocaine has been shown to decrease the incidence of pain

Currently, most centers utilize an anesthesiologist or nurse anesthetist to administer propofol (Sury & Smith, 2008), although recently nurse administered and patient controlled dosing has been reported in adult patients. In our endoscopy center, propofol is also administered by an anesthesiologist or nurse anesthetist. Propofol provides equal or better control and more rapid recovery when compared with midazolam for sedation (O'Hare et al., 2001). Initial intravenous bolus dose of propofol is 1.0 mg/kg and is followed by 0.5 mg/kg, and the repeated dose is needed. In my experience, I use the initial bolus dose of propofol and follow by the continuous intravenous technique. The continuous intravenous infusion of propofol dose is 100-150 mcg/kg/min. Majority of our patients received propofol in combination with other sedatives. Over the last decade, the use of propofol for endoscopic sedation has increased. It has gained wide acceptance among adult

hour (Tolia et al., 2000).

**3.2 Sedative drugs 3.2.1 Propofol** 

during injection (Bassett et al., 2003).

**3.1.2 Meperidine (Pethidine)** 

Midazolam is the drug most commonly used for sedation in children during procedures (Kennedy et al., 1998; Pena & Krauss, 1999). It is a shorting, water soluble benzodiazepine with anxiolytic, amnestic, sedative, muscle relaxant, and anticonvulsant properties. It is very widely used because of its more rapid onset of action and shorter duration of effect compared with diazepam (Tolia et al., 2000). Disadvantages of midazolam include transient hypotension and vomiting. Midazolam is approved for many routes, including intravenous, oral and nasal and is most useful for intravenous sedation. Because of greater clearance of midazolam in children, larger weight-adjusted dosages may be required in pediatric patients than in adult to achieve similar levels and duration of sedation (Gilger, 1993 & Tolia et al., 2000). The shorter clinical half-life of the drug necessitates additional boluses for longer or complicated procedures. Less midazolam is needed when fentanyl is administered than when meperidine is given with midazolam. Initial intravenous dose of midazolam is 0.025-0.1 mg/kg and may repeat another dose, but the maximum recommended dose is 0.4- 0.6 mg/kg. In our endoscopy center, we commonly use midazolam combined with low dose propofol and/or low dose fentanyl.

#### **3.2.3 Ketamine**

Ketamine is a phencyclidine derivative with dissociative sedative, analgesic and amnestic properties (Green & Krauss, 2000). It is one of the most sedative-analgesic agents and results in a number of desired clinical effects that are dose dependent (Krystal et al., 1994). Typically spontaneous respiration and airway reflexes are maintained although may not be totally normal. Neuropsychiatric effects of ketamine include visual hallucinations that may be accompanied by emergence phenomena and agitation. Ketamine generally causes an increase in heart rate, blood pressure, cardiac output, intracranial pressure, and intraocular pressure. Ketamine can induce salivation, and cholinergics have traditionally been coadministered. The single most severe adverse effect with ketamine sedation is laryngospasm. Ketamine is clinically effective by a number of different routes. Intravenous dose of ketamine is 1-1.5 mg/kg, and may repeat dose every 10 minutes as needed. In Thailand, we commonly used low dose of ketamine, and combined with low dose of midazolam, opioid drug, and/or low dose of propofol (Amornyotin et al., 2009). This combination technique produces stable hemodynamic effects, and can reduce the sedation related adverse effects.

The ideal combination of sedative drugs for intravenous sedation in pediatric patients undergoing gastrointestinal endoscopic procedure is unknown. The drug combination provides synergistic action while lowering the doses of each agent. The combination regimen may be a superior sedation technique (Cohen et al., 2004; Van Natta & Rex, 2006). Our practice reflects this technique where many different combination regimens were used. Midazolam and fentanyl are the most common agents used in combination with propofol in this study. The next most common combination includes midazolam, fentanyl, ketamine, and propofol.

Intravenous Sedation for Pediatric Gastrointestinal Endoscopy in a Developing Country 59

American Society of Anesthesiologists. (2002). Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology*, Vol. 96, No. 4, pp. 1004-1017 Amornyotin S. et al. (2009). Experience of intravenous sedation for pediatric gastrointestinal

Amornyotin, S. & Aanpreung, P. (2010). Clinical effectiveness of an anesthesiologist-

*Pediatrics*, Vol. 2010, Article. ID 748564, 6 pages, doi:10.1155/2010/748564 Aouad M.T. et al. (2008). Addition of ketamine to propofol for initiation of procedural

stability. *Acta Anaesthesiologica Scandinavica*, Vol. 52, No. 4, pp. 561–565 Barbi E. et al. (2006). Deep sedation with propofol for upper gastrointestinal endoscopy in

with emphasis on side effects. *Endoscopy*, Vol. 38, No. 4, pp. 368–375 Bahal-O'Mara N. et al. (1993). Efficacy of diazepam and meperidine in ambulatory pediatric

*Pediatric Gastroenterology and Nutrition,* Vol. 16, No. 4, pp. 387-392

review. *Gastrointestinal Endoscopy,* Vol. 45, No. 5, pp. 375–380

*Anesthesia,* Vol. 19, No. 8, pp. 784-791

*Endoscopy*, Vol. 59, No. 7, pp. 795–803

*Pediatrics,* Vol. 118, No. 6, pp. 2587-2602

*Gastroenterology Nursing,* Vol. 16, No. 2, pp. 75-79

Accreditation of Healthcare Organizations

pp. 1097-1103

No. 7, pp. 257-262

Vol. 36, No. 5, pp. 480-482

endoscopy in a large tertiary referral center in a developing country. *Pediatric* 

administered intravenous sedation outside of the main operating room for pediatric upper gastrointestinal endoscopy in Thailand. *International Journal of* 

anesthesia in children reduces propofol consumption and preserves hemodynamic

children, administered by specially trained pediatricians: a prospective case series

patients undergoing endoscopy: a randomized, double-blind trial. *Journal of* 

endoscopic examinations in children, adolescents, and young adults: a twelve-year

pediatric experience. *Archieves of Pediatric and Adolescent Medicine*, Vol. 157, No. 11,

using lowdose propofol, meperidine fentanyl, and midazolam. *Gastrointestinal* 

during and after sedation for diagnostic and therapeutic procedures: an update.

endoscopic procedures: a review. *World Journal of Gastrointestinal Endoscopy,* Vol. 2,

Balsells F. et al. (1997). Use of conscious sedation for lower and upper gastrointestinal

Barbi E. et al. (2003). Deep sedation with propofol by nonanesthesiologists: a prospective

Bassett K.E. et al. (2003). Propofol for procedural sedation in children in the emergency department. *Annals of Emergency Medicine,* Vol. 42, No. 6, pp. 773-782 Cohen L.B. et al. (2004). Moderate level sedation during endoscopy: a prospective study

Cote C.J. et al. (2006). Guidelines for monitoring and management of pediatric patients

Dar, A.Q. & Shah, Z.A. (2010). Anesthesia and sedation in pediatric gastrointestinal

Gilger M.A. (1993). Conscious sedation for endoscopy in the pediatric patient.

Green, S.M. & Krauss, B. (2000). The semantics of ketamine. *Annals of Emergency Medicine,*

Green, S.M. & Krauss, B. (2003). Propofol in emergency medicine: pushing the sedation

Joint Commission on Accreditation of Healthcare Organizations. (2005). Comprehensive

Kaddu R. et al. (2002). Propofol compared with general anesthesia for pediatric GI endoscopy: is propofol better? *Gastrointestinal Endoscopy,* Vol. 55, No. 1, pp. 27–32 Kennedy R.M. et al. (1998). Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthropedic emergencies. *Pediatrics*, Vol. 102, No. 4, pp. 956-963

accreditation manual for hospitals. Oakbrook Terrace, IL: Joint Commission on

frontier," *Annals of Emergency Medicine*, Vol. 42, No. 6, pp. 792-797

Cardiopulmonary complications account for more than half of the major complications during endoscopy (Lamireau et al., 1998) and are often related to hypoxia, especially in children less than 1-year old (Lamireau et al., 1998 & Lightdale et al., 2008). In a study by Barbi et al., using propofol in 811 children undergoing upper endoscopy, desaturation on supplemental oxygen is 3%, and major desaturation was noted in 0.7% of all the children. Additionally, a study by Yldzdas et al. demonstrated that the use propofol and midazolam fentanyl in 126 children who were randomly assigned to different sedation regimens had a 16.6% incidence of respiratory depression as shown by high end-tidal carbon dioxide (>50 mmHg). The higher incidence of respiratory depression reflected the better detection of respiratory depression by the use of end-tidal carbon dioxide. The adverse events in our clinical practice are comparable to those in the studies that did not use end-tidal carbon dioxide monitoring (Balsells et al., 1997; Malviya et al., 1997 & Barbi et al., 2006).
